Clinical trial · Observational
Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients
Phase 1 Prospective Study of Markers of Ovarian Reserve in Young Female Cancer Patients
NCT00930501CI-TRIAL-00002418OvrescancerunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
young female cancer patients have improving chances of survival. the main risk is a chronic damage to their ovarian reserve. This may lead to future infertility.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Infertility | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood tests | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cancer patients
- description
- women 5-45 yr olf pre and post chemotherapy
- interventionNames
- Biological: blood tests
Primary outcomes (1)
- measure
- Anti mullerian hormone
- timeFrame
- 2 years
Secondary outcomes (5)
- measure
- antral follicle count
- timeFrame
- 2 years
- measure
- FSH
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 5 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * all females prior and after chemotherapy Exclusion Criteria: * do not consent
References
Publications (0)
Data not yet available
No reference posted for this study.